Tocilizumab and adalimumab in an 18q deletion syndrome patient with chronic arthritis.
S. Kashima,S. Tsuchida,H. Koizumi
Clinical and Experimental Rheumatology
Abstract:Sirs, A case of 18q deletion syndrome (18qsyndrome) was reported in 1964 by De Grouchy et al.; the syndrome exhibits diverse symptoms such as mental retardation, short stature, and poor muscle tone (1). Some studies have reported an association between chromosome 18 and immunocompetence. For example, the haplo-insufficiency of the 18q22.3-q23 gene region may be associated with the immunoglobulin A deficiency phenotype (2), and chromosome 18 may contain a locus that is responsible for the regulation of both Th1 and Th2 cytokine production (3). Here we report the case of a patient with 18q-syndrome and an autoimmune disease of chronic arthritis. A 10-month-old girl who was unable to crawl underwent a genetic screening that revealed the presence of 18q-syndrome [46, xx, del (18)(q22-qter)]. She had delayed mental development, whereas no malformation and abnormality were observed in motor development. The girl developed nephrotic syndrome (NS) at the age of 1 year; her kidney function had a waxing and waning course until 7 years of age. The immunosuppressive drugs for the NS included methylprednisolone, mizoribine, and cyclosporine. After a successful course of treatment, the mizoribine and cyclosporine were discontinued at the age of 11 years and 7 months. One month later, she complained of general malaise, a loss of appetite, and joint pain, and she was then referred to the pediatric department in our hospital. Biochemical examination of her blood showed the following results: white blood cells, 8,900/μL; haemoglobin, 14.8 g/dL; platelets, 35.5 × 104/μL; erythrocyte sedimentation rate, 123 mm/h; C-reactive protein, 2.81 mg/dL; rheumatoid factor, 469.8 IU/mL; 50% haemolytic unit of complement, 61.9 U/mL; ferritin, 114 ng/mL; antinuclear antibody, <80 times the normal; matrix metalloproteinase-3 (MMP-3), 195 ng/mL; anti-cyclic citrullinated peptide antibody, 293 U/mL; immunoglobulin G, 830 mg/dL; immunoglobulin A, 188 mg/ dL; immunoglobulin M, 411 mg/dL; immunoglobulin D, 10.7 mg/dL; interleukin-6, 113 pg/mL; soluble interleukin-2 receptor, 812 U/mL; and tumour necrosis factor-α, 1.4 pg/mL. The prototypes of the HLA allele were HLA-A*24:31, B*71:51, and DRB1*04:14. She complained of pain in her neck, both hands, and her wrists. Magnetic resonance imaging (MRI) revealed irregular patterns of the dens, bilateral carpals, and the distal radius as well as synovial inflammation with fibrosis that contributed to the low signal intensity on the T1-weighted images and the high signal intensity on the T2-weighted images. Accordingly, the patient was diagnosed with inflammatory arthropathies. She was treated with methotrexate 5 mg/m2/week (Japanese initial dose), ibuprofen 10 mg/kg/day, and prednisolone 2 mg/kg/day; however, MRI showed more extensive synovial inflammation in the radius after 2 months because the methotrexate dose was extremely insufficient to manage her inflammation. Increasing the dose of methotrexate to 14 mg/m2/ week and ibuprofen to 20 mg/kg resolved her pain, but her movement was limited to walking with assistance. High dose methotrexate for a year did not decrease the limitations of her ankle joints; thus, tocilizumab was added to the methotrexate. After the tocilizumab (8 mg/kg/dose) was initiated, the joint limitation were resolved without any side effects, and the level of MMP-3 decreased by 53.7 ng/mL. However, she occasionally had pain in her wrists and right ankle; the ultrasound examination showed increased blood flow to the lunate bone and that the synovium of the right lateral malleolus had thickened. After 14 months of treatment with tocilizumab and one week of wash-out, the treatment was changed to adalimumab 40 mg (1.1 mg/kg/dose) every 2 weeks; she was free of any pain, stiffness, or recurrence just 2 months after its introduction. The level of MMP-3 decreased by 39.0 ng/mL, and the ultrasound examination showed no thickened synovium or increased blood flow. This patient had also been treated for NS. Immunosuppressant treatment can potentially improve the pain in inflammatory arthropathies; however, she developed joint pain when the immunosuppressant was slowly tapered. Some studies have reported an association between chromosome 18 and immunocompetency; haplo-insufficiency of the 18q22.3-q23 gene region might cause the immunoglobulin A deficiency phenotype (2), and chromosome 18 has a locus that is responsible for the regulation of both Th1 and Th2 cytokine production (3). Moreover, single nucleotide polymorphisms have been